# Mesoblast (MESO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MESO
## Company Profile
- Ticker: MESO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
- Tags: Stem Cells
## Stock Data
- Close: 16.39 USD
- Market cap: 1877182684.08 USD
- Last updated: 2026-09-08
## Business Overview
Mesoblast is a regenerative medicine company focused on cell-based therapies for inflammatory and degenerative diseases. Its platform has long centered on developing allogeneic cell therapies with broad medical use.
## Why The Stock Is Moving

As of Sep 8, 2026, MESO closed down 5.37% at $16.39. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in Australia and listed in the U.S. as an ADR, Mesoblast sits in cell therapy and regenerative medicine.

## Business Model

The company depends on clinical validation, manufacturing execution, and the ability to commercialize cell-based medicine.

## Landscape Position

Mesoblast is a long-running regenerative-medicine name whose valuation depends on clinical and commercial milestones.

## Future Catalysts

- Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion. The stock will care about whether the commercial base keeps building.

## Recent News
- 2026-06-02 01:51 EST — [ASX CEO Connect Presentation](https://biopharmsignal.com/news/MESO/asx-ceo-connect-presentation) — Source: Mesoblast
- 2026-04-29 23:56 EST — [Quarterly Activities/Appendix 4C Cash Flow Report](https://biopharmsignal.com/news/MESO/quarterly-activities-appendix-4c-cash-flow-report) — Source: Mesoblast
- 2026-04-28 23:50 EST — [Patient Recruitment Target Achieved in CLBP Pivotal Trial](https://biopharmsignal.com/news/MESO/patient-recruitment-target-achieved-in-clbp-pivotal-trial) — Source: Mesoblast
- 2026-04-16 07:22 EST — [Appendix 3Y for Gregory George](https://biopharmsignal.com/news/MESO/appendix-3y-for-gregory-george) — Source: Mesoblast
- 2026-04-16 07:13 EST — [Notification of cessation of securities - MSB](https://biopharmsignal.com/news/MESO/notification-of-cessation-of-securities-msb) — Source: Mesoblast